Canada's Biggest Cell And Gene Therapy Manufacturing Facility Opens In Hamilton

Canada’s Biggest Cell And Gene Therapy Manufacturing Facility Opens In Hamilton

Located in the McMaster Innovation Park, OmniaBio’s new facility the largest of its kind in Canada

OmniaBio Inc. announced the opening of a new cell and gene therapy (CGT) manufacturing and artificial intelligence facility, making it Canada’s largest contract development and manufacturing organization facility dedicated to cell and gene therapy.

The new 120,000-square-foot facility is located within the McMaster Innovation Park close to the U.S. border and Canada’s largest international airport.

Built with financial support from Invest Ontario, OmniaBio’s new biomanufacturing facility in Hamilton accounts for an overall project investment of over $580 million and is expected to create 250 skilled jobs. The new facility is designed to meet specialized cell and gene therapy manufacturing needs by using advanced technologies such as robotics, biosensors and machine learning, helping to reduce costs, improve product quality and increase production rates compared to conventional CDMO approaches.

OmniaBio will collaborate with pharmaceutical and biotech companies and academic centres to offer a range of services from process, analytical and associated AI development to commercial manufacturing.

The new facility’s first commercial-stage customer, Medipost plans to manufacture its allogeneic umbilical-cord-blood–derived mesenchymal stem cell (MSC) product, Cartistem, which is used to treat patients with osteoarthritis caused by degeneration.

Initially founded by Canada’s Centre for Commercialization of Regenerative Medicine (CCRM) South Korean stem-cell therapeutics developer Medipost Co., Ltd. joined CCRM in the partnership owning OmniaBio.

Since Ontario scientists discovered stem cells in the 1960s, the province has emerged as a leader in life sciences research and development. Today it has Canada’s largest concentrations of life science firms with close to 2,000 companies ranging from multinational pharmaceuticals to startups.

In a statement, OmniaBio CEO Mitchel Sivilotti said, “OmniaBio is partnering with clients to make these essential therapies more accessible and affordable for patients in North America and worldwide. This new facility puts us in a unique position as a specialist commercial CGT manufacturing leader tackling the toughest disease challenges head-on by combining an experienced team with advanced tools and solutions.”

“This facility is a game-changer as it will keep revolutionary companies in Canada and attract global leaders to our ecosystem. With manufacturing, we have the ingredients to see the ecosystem thrive,” added Michael May, president and CEO of CCRM and the chair of OmniaBio’s board.

Source CoStar. Click here for the full story.

You must be logged in to post a comment